<i>BRAF</i>Gene Mutations Are Rare Events in Gastroenteropancreatic Neuroendocrine Tumors

Andrea Tannapfel(Leipzig University), Dieter Hörsch(Philipps University of Marburg)

American Journal of Clinical Pathology

February 1, 2005

10.1309/yqbr9c05ru4dd3rn

Cited by 44

Related Papers

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

|Annals of Oncology|2016|344

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

|Neuroendocrinology|2017|331

<i>TFAP2E–DKK4</i> and Chemoresistance in Colorectal Cancer

|New England Journal of Medicine|2012|184

Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma

|JNCI Journal of the National Cancer Institute|1999|162